Recent Winners On GuerillaStockTrading


+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days
+4%
WLH
Alert Price: $19.94
High Price: $20.75
Results: 4% in 13 Days
+4%
AMAT
Alert Price: $31.53
High Price: $32.69
Results: 4% in 9 Days
+4%
TAST
Alert Price: $14.05
High Price: $14.55
Results: 4% in 21 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.


Top Catalysts For The Week Ending January 20 2017


Sanchez Energy = Eagleford Acquisition Doubles Drilling Inventory

Mobileye = Goldman Sachs Raised Mobileye To A Buy Rating

Tesla = Expanding Investment In Gigafactory by $350 Million, Adding 550 New Jobs To Make Model 3

AbbVie = Gets FDA Approval For Imbruvica

3D Systems = Hearing Takeover Rumors Circulating About GE

International Game Technology = Wins Big Contract From Svenska Spel in Sweden

WiLAN = Court of Appeals Grants WiLAN Positive Rulings In Case Against Ericsson

Gilead Sciences = Hearing Takeover Rumors Circulating

Juno = Hearing Juno Takeover Rumors Circulating

Fusion Telecommunications = Awarded 3-year $100K For Managed Cloud Services

Teva Pharmaceutical = Receives FDA Approval For Vantrela ER

EPAM Systems = Lands Giant UBS Multi-year Agreement Valued At Over $300 Million

Tutor Perini Building = Receives Notice of Intent To Award a $1.37 Billion Contract From Los Angeles County

Amicus Therapeutics = Hearing Takeover Rumors Circulating

CEMEX = Trump Build That Wall Play

Iridium Communications = Announces Successful First Launch For Space-Based ADS-B Network

Applied Optoelectronics = Play On Switch From Copper To Optical Interconnect Inside Datacenters

3D Systems = Expands its Virtual Surgical Planning Service to Include Cranial Applications

pp250x250

Trading Lessons

Mainstream Financial News

Archives

Hearing Takeover Rumors Circulating About ACADIA Pharmaceuticals

Follow Us on StockTwits

January 4, 2017: Hearing takeover rumors circulating about biotechnology firm ACADIA Pharmaceuticals. The rumor is that Pfizer is interested in buying ACADIA Pharmaceuticals in the $45 per share price range. Could not find the source of the rumors.

December 21, 2016: H.C. Wainwright & Co./ Rodman & Renshaw reiterates a Buy rating on ACADIA Pharmaceuticals and sets a price target of $60.

December 20, 2016: Needham reiterates a Buy rating on ACADIA Pharmaceuticals and sets a price target of $49. Needham likes the positive results from a Phase 2 trial of Nuplazid in Alzheimer’s Disease Psychosis (ADP).

December 20, 2016: ACADIA Pharmaceuticals announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimers disease psychosis (AD Psychosis). As a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors, pimavanserin has a different biological mechanism than other marketed antipsychotics. Pimavanserin has been approved by the United States Food and Drug Administration (FDA) for hallucinations and delusions associated with Parkinsons disease psychosis and currently is being studied in several other disease states, including AD Psychosis. The FDA has not approved any drug to treat AD Psychosis.

In this Phase II exploratory study, pimavanserin met the primary endpoint showing a statistically significant reduction in psychosis versus placebo as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis score at week 6 of dosing (p=0.0451). Pimavanserin was generally well-tolerated and the safety profile was consistent with what has been observed in previous studies.

ACADIA Pharmaceuticals Stock Chart

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

StockTwits

Trading The News: ACADIA Pharmaceuticals In The News